双靶点烟酰胺磷酸核糖转移酶/组蛋白去乙酰化酶抑制剂作为多靶点抗肿瘤药物发现的新策略
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.
作者信息
Chen Wei, Dong Guoqiang, Wu Ying, Zhang Wannian, Miao Chaoyu, Sheng Chunquan
机构信息
School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People's Republic of China.
出版信息
ACS Med Chem Lett. 2017 Dec 14;9(1):34-38. doi: 10.1021/acsmedchemlett.7b00414. eCollection 2018 Jan 11.
Abstract
Novel dual nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) inhibitors were designed by a pharmacophore fusion approach. The thiazolocarboxamide inhibitors were highly active for both targets. In particular, compound (NAMPT IC = 15 nM, HDAC1 IC = 2 nM) showed potent antitumor efficacy in the HCT116 xenograft model. The study offers a new strategy for multitarget antitumor drug discovery by simultaneously acting on cancer metabolism and epigenetics.
摘要
通过药效团融合方法设计了新型双功能烟酰胺磷酸核糖转移酶（NAMPT）和组蛋白去乙酰化酶（HDAC）抑制剂。噻唑甲酰胺抑制剂对这两个靶点均具有高活性。特别是化合物（NAMPT IC = 15 nM，HDAC1 IC = 2 nM）在HCT116异种移植模型中显示出强效的抗肿瘤功效。该研究为通过同时作用于癌症代谢和表观遗传学来发现多靶点抗肿瘤药物提供了一种新策略。
相似文献
1
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.双靶点烟酰胺磷酸核糖转移酶/组蛋白去乙酰化酶抑制剂作为多靶点抗肿瘤药物发现的新策略
ACS Med Chem Lett. 2017 Dec 14;9(1):34-38. doi: 10.1021/acsmedchemlett.7b00414. eCollection 2018 Jan 11.
2
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.同时靶向癌症代谢和表观遗传学的小分子抑制剂：新型烟酰胺磷酸核糖基转移酶（NAMPT）和组蛋白去乙酰化酶（HDAC）双重抑制剂的发现
J Med Chem. 2017 Oct 12;60(19):7965-7983. doi: 10.1021/acs.jmedchem.7b00467. Epub 2017 Sep 21.
3
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.HDAC/NAMPT 双重抑制剂克服了 p53 缺失白血病细胞的初始耐药性。
Eur J Med Chem. 2024 Feb 15;266:116127. doi: 10.1016/j.ejmech.2024.116127. Epub 2024 Jan 5.
4
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.新型吲哚胺2,3-双加氧酶1（IDO1）和组蛋白去乙酰化酶（HDAC）双重抑制剂的发现。
ACS Med Chem Lett. 2018 Mar 26;9(4):312-317. doi: 10.1021/acsmedchemlett.7b00487. eCollection 2018 Apr 12.
5
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.烟酰胺磷酸核糖转移酶（NAMPT）是抗肿瘤药物西达本胺的新靶点。
ACS Med Chem Lett. 2019 Dec 13;11(1):40-44. doi: 10.1021/acsmedchemlett.9b00407. eCollection 2020 Jan 9.
6
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.小分子同时抑制 p53-鼠双微体 2（MDM2）相互作用和组蛋白去乙酰化酶（HDACs）：新型多靶点抗肿瘤药物的发现。
J Med Chem. 2018 Aug 23;61(16):7245-7260. doi: 10.1021/acs.jmedchem.8b00664. Epub 2018 Aug 9.
7
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.基于结构的新型含酰胺烟酰胺磷酸核糖基转移酶（NAMPT）抑制剂的发现。
J Med Chem. 2013 Aug 22;56(16):6413-33. doi: 10.1021/jm4008664. Epub 2013 Jul 31.
8
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.具有强大抗肿瘤活性的以吴茱萸碱为灵感的组蛋白去乙酰化酶1（HDAC1）和拓扑异构酶2（TOP2）双重抑制剂。
Acta Pharm Sin B. 2020 Jul;10(7):1294-1308. doi: 10.1016/j.apsb.2019.11.011. Epub 2019 Nov 21.
9
Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.发现有效且强效的含氰胍的烟酰胺磷酸核糖基转移酶（Nampt）抑制剂。
Bioorg Med Chem Lett. 2014 Jan 1;24(1):337-43. doi: 10.1016/j.bmcl.2013.11.006. Epub 2013 Nov 14.
10
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.基于结构的新型烟酰胺磷酸核糖基转移酶（Nampt）抑制剂的鉴定。
J Med Chem. 2013 Jun 27;56(12):4921-37. doi: 10.1021/jm400186h. Epub 2013 Jun 13.
引用本文的文献
1
Design and synthesis of thiazole-based hydroxamate histone deacetylase inhibitors with potent antitumor efficacy by inducing apoptosis, pyroptosis and cell cycle arrest.基于噻唑的异羟肟酸类组蛋白去乙酰化酶抑制剂的设计与合成，通过诱导凋亡、焦亡和细胞周期阻滞发挥强大的抗肿瘤功效。
Sci Rep. 2025 Jul 9;15(1):24589. doi: 10.1038/s41598-025-08474-5.
2
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.组蛋白去乙酰化酶/微管蛋白双靶点抑制剂开发的最新进展
Pharmaceuticals (Basel). 2025 Feb 27;18(3):341. doi: 10.3390/ph18030341.
3
Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents.靶向 NAD 代谢：作为抗乳腺癌剂的 NAMPT/PARP1 双重靶标抑制剂的合理设计、合成和体外评价。
Molecules. 2024 Jun 14;29(12):2836. doi: 10.3390/molecules29122836.
4
Distinct Capabilities in NAD Metabolism Mediate Resistance to NAMPT Inhibition in Glioblastoma.NAD代谢中的独特能力介导胶质母细胞瘤对NAMPT抑制的抗性。
Cancers (Basel). 2024 May 29;16(11):2054. doi: 10.3390/cancers16112054.
5
Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.引导烟酰胺磷酸核糖转移酶（NAMPT）来应对生死问题。
J Med Chem. 2024 Apr 25;67(8):5999-6026. doi: 10.1021/acs.jmedchem.3c02112. Epub 2024 Apr 5.
6
Targeting histone deacetylases for cancer therapy: Trends and challenges.以组蛋白去乙酰化酶为靶点进行癌症治疗：趋势与挑战。
Acta Pharm Sin B. 2023 Jun;13(6):2425-2463. doi: 10.1016/j.apsb.2023.02.007. Epub 2023 Feb 18.
7
Review of various NAMPT inhibitors for the treatment of cancer.用于治疗癌症的各种烟酰胺磷酸核糖转移酶（NAMPT）抑制剂的综述。
Front Pharmacol. 2022 Sep 7;13:970553. doi: 10.3389/fphar.2022.970553. eCollection 2022.
8
From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.从限速酶到治疗靶点：烟酰胺磷酸核糖转移酶在神经退行性疾病中的前景
Front Pharmacol. 2022 Jul 12;13:920113. doi: 10.3389/fphar.2022.920113. eCollection 2022.
9
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).PROTACs：学术和工业界的巨大机遇（2020 年至 2021 年更新）。
Signal Transduct Target Ther. 2022 Jun 9;7(1):181. doi: 10.1038/s41392-022-00999-9.
10
Histone Deacetylase Inhibitory Activity and Antiproliferative Potential of New [6]-Shogaol Derivatives.新型[6]-姜烯酚衍生物的组蛋白去乙酰化酶抑制活性和抗增殖潜力。
Molecules. 2022 May 22;27(10):3332. doi: 10.3390/molecules27103332.
本文引用的文献
1
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.同时靶向癌症代谢和表观遗传学的小分子抑制剂：新型烟酰胺磷酸核糖基转移酶（NAMPT）和组蛋白去乙酰化酶（HDAC）双重抑制剂的发现
J Med Chem. 2017 Oct 12;60(19):7965-7983. doi: 10.1021/acs.jmedchem.7b00467. Epub 2017 Sep 21.
2
Inhibitors of histone deacetylase as antitumor agents: A critical review.组蛋白去乙酰化酶抑制剂作为抗肿瘤药物的综述：批判性评价
Bioorg Chem. 2016 Aug;67:18-42. doi: 10.1016/j.bioorg.2016.05.005. Epub 2016 May 17.
3
Panobinostat for the treatment of multiple myeloma: the evidence to date.帕比司他用于治疗多发性骨髓瘤：迄今的证据
J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015.
4
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.靶向烟酰胺磷酸核糖转移酶的新型小分子抑制剂的发现与表征
Sci Rep. 2015 Jun 4;5:10043. doi: 10.1038/srep10043.
5
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.新型多作用拓扑异构酶I/II和组蛋白脱乙酰酶抑制剂的发现。
ACS Med Chem Lett. 2015 Jan 14;6(3):239-43. doi: 10.1021/ml500327q. eCollection 2015 Mar 12.
6
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.抑制烟酰胺磷酸核糖转移酶（NAMPT）作为癌症治疗策略。
Pharmacol Ther. 2015 Jul;151:16-31. doi: 10.1016/j.pharmthera.2015.02.004. Epub 2015 Feb 21.
7
Epigenetics: novel therapeutics targeting epigenetics.表观遗传学：针对表观遗传学的新型疗法。
J Med Chem. 2015 Jan 22;58(2):523-4. doi: 10.1021/jm501941q. Epub 2014 Dec 22.
8
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.组蛋白去乙酰化酶及其抑制剂在癌症、神经疾病和免疫紊乱中的作用。
Nat Rev Drug Discov. 2014 Sep;13(9):673-91. doi: 10.1038/nrd4360. Epub 2014 Aug 18.
9
Polypharmacology: challenges and opportunities in drug discovery.多药理学：药物研发中的挑战与机遇
J Med Chem. 2014 Oct 9;57(19):7874-87. doi: 10.1021/jm5006463. Epub 2014 Jun 25.
10
Thiazolocarboxamide Analogues as NAMPT Inhibitors.噻唑甲酰胺类似物作为烟酰胺磷酸核糖转移酶（NAMPT）抑制剂
ACS Med Chem Lett. 2014 Feb 13;5(4):277. doi: 10.1021/ml500046t. eCollection 2014 Apr 10.
Zotero 插件